2 completed, 2 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 1 | Completed 1 |
Follow Stemcentrx: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer Rovalpituzumab Tesirine - Small Cell Lung Carcinoma | Phase 1 | Completed | Stemcentrx | 46 | 2016-09-01 | 2018-09-24 |
| Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer SC-003, SC-003 in combination with ABBV-181 - Ovarian Cancer | Phase 1 | Terminated | Stemcentrx | 74 | 2015-08-01 | 2019-01-04 |
| SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma SC-002 - Small Cell Lung Cancer | Phase 1 | Terminated | Stemcentrx | 35 | 2015-06-01 | 2018-10-05 |
| Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Rovalpituzumab tesirine (SC16LD6.5) - Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Stemcentrx | 82 | 2013-07-01 | 2018-08-09 |
Small Cell Lung Carcinoma (3) · Ovarian Neoplasms (1)
rovalpituzumab tesirine (2) · SC002 (1) · budigalimab (1)
United States (4) · Canada (1)
Julia Lawrence, D.O. (2) · Daniel Da Costa, PharmD (1) · Donald Strickland, MD (1)